Taylor & Francis Group
Browse
uasa_a_1981338_sm8978.pdf (449.8 kB)

Model-Robust Inference for Clinical Trials that Improve Precision by Stratified Randomization and Covariate Adjustment

Download (449.8 kB)
journal contribution
posted on 2021-09-16, 21:00 authored by Bingkai Wang, Ryoko Susukida, Ramin Mojtabai, Masoumeh Amin-Esmaeili, Michael Rosenblum

Two commonly used methods for improving precision and power in clinical trials are stratified randomization and covariate adjustment. However, many trials do not fully capitalize on the combined precision gains from these two methods, which can lead to wasted resources in terms of sample size and trial duration. We derive consistency and asymptotic normality of model-robust estimators that combine these two methods, and show that these estimators can lead to substantial gains in precision and power. Our theorems cover a class of estimators that handle continuous, binary, and time-to-event outcomes; missing outcomes under the missing at random assumption are handled as well. For each estimator, we give a formula for a consistent variance estimator that is model-robust and that fully captures variance reductions from stratified randomization and covariate adjustment. Also, we give the first proof (to the best of our knowledge) of consistency and asymptotic normality of the Kaplan–Meier estimator under stratified randomization, and we derive its asymptotic variance. The above results also hold for the biased-coin covariate-adaptive design. We demonstrate our results using data from three trials of substance use disorder treatments, where the variance reduction due to stratified randomization and covariate adjustment ranges from 1% to 36%. Supplementary materials for this article, including a standardized description of the materials available for reproducing the work, are available as an online supplement.

Funding

This project was supported by a research award from Arnold Ventures. The information reported here results from secondary analyses of data from clinical trials conducted by the National Institute on Drug Abuse (NIDA). Specifically, data from NIDA–CTN-0003 (Suboxone (Buprenorphine/Naloxone) Taper: A Comparison of Two Schedules), NIDA-CTN-0030 (A Two-Phase Randomized Controlled Clinical Trial of Buprenorphine/Naloxone Treatment Plus Individual Drug Counseling for Opioid Analgesic Dependence) and NIDA-CTN-0044 (Web-delivery of Evidence-Based, Psychosocial Treatment for Substance Use Disorders) were included. NIDA databases and information are available at (https://datashare.nida.nih.gov). MR was supported by the Johns Hopkins Center of Excellence in Regulatory Science and Innovation, which is funded by the Food and Drug Administration (FDA) of the U.S. Department of Health and Human Services (HHS) as part of a financial assistance award (U01FD005942). The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement, by any of the aforementioned organizations, the FDA/HHS, nor the U.S. Government.

History